To determine whether prehospital nonsteroidal anti-inflammatory drug (NSAID) use may lead to a reduced incidence of trauma-induced coagulopathy (TIC) in severely injured patients. Background: TIC is present in up to a quarter of severely injured trauma patients and is linked to worse outcomes after injury. Evidence linking TIC to inflammation has emerged; however, the mechanism behind this association is still under investigation. NSAIDs are commonly used anti-inflammatory drugs, but their effects on TIC and outcomes after injury are largely unexplored. Methods: We performed a secondary analysis of the Inflammation and the Host Response to Injury Large Scale Collaborative Program (Glue Grant) data set. Prehospital medications and comorbidities were analyzed by logistic regression analysis for association with TIC as defined by laboratory (international normalized ratio >1.5) or clinical (transfusion >2 units of fresh frozen plasma or >1 pack of platelets in 6 hours) parameters. Results: Prehospital NSIAD use was independently associated with a 72% lower risk of TIC and was the only medication among 15 analyzed to retain significance in the model. Stepwise logistic regression also demonstrated that preadmission use of NSAIDs was independently associated with a 66% lower risk of clinically significant coagulopathy. These findings were independent of comorbid conditions linked to NSAID use. Conclusions: NSAID use before admission for severe injury is associated with a reduced incidence of TIC. These findings provide further evidence to a potential leak between TIC and inflammation.
anticoagulation. 1 Early coagulopathy in trauma has recently been shown to be associated with a greater incidence of multiple-organ failure and nosocomial infection and substantially higher transfusion requirements. 2, 3 Importantly, coagulopathy upon presentation to the emergency department has been associated with both early and late mortality. 3 Although TIC has been increasingly recognized as a critical component of the pathophysiology of trauma and hemorrhagic shock, factors that predict the development of TIC remain largely unexplored. 4 The lack of ability to predict TIC makes the design of therapeutic interventions challenging, especially considering that TIC seems to develop rapidly and early after injury.
Despite the significance of TIC, little is known about the pathogenesis of this perturbation in normal coagulation. Hyperfibrinolysis, factor V inhibition, and impaired platelet function, among others, have been implicated in the development of TIC. 5 Laboratory data and prospective analysis from severely injured trauma patients have linked the development of TIC to alterations in the thrombomodulinprotein C pathway and excessive activated protein C activation, resulting in impaired coagulation. [6] [7] [8] These data present a potential link between TIC and inflammation, which is a common finding in other conditions where both sterile (such as myocardial infarction) and pathogen-mediated (sepsis) diseases present with coagulopathy. 9 We 10 and others 11, 12 have previously examined the effects of prehospital medications with anti-inflammatory properties on outcomes in traumatic injury. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of medications widely used for their antiinflammatory effects. However, the role of prehospital use of NSAIDs in outcomes after traumatic injury remains largely unexplored. Given the proposed link between inflammation and coagulopathy, we hypothesized that prehospital NSAID use may lead to a reduced incidence of TIC in severely injured patients.
METHODS
Data were obtained from the Inflammation and the Host Response to Injury Large Scale Collaborative Program (www.gluegrant .org), supported by the National Institute of General Medical Sciences, which is a multicenter prospective cohort study of adults presenting with hemorrhagic shock after blunt injury designed to characterize the genomic and proteomic response after injury. 13 Patients admitted to 1 of 7 institutions during an 8-year period (2003-2010) were included. Inclusion criteria for the overall cohort study included blunt mechanism, presence of prehospital or emergency department hypotension (systolic blood pressure <90 mm Hg) or an elevated base deficit (>6 mEq/L), blood transfusion requirement within the first 12 hours, and any body region exclusive of the brain with an abbreviated injury score of 2 or more, allowing exclusion of patients with isolated traumatic brain injury. Patients either younger than 18 years or older than 90 years and those with cervical spinal cord injury were also excluded. Clinical data were entered and stored in TrialDB, a Web-based data collection platform, by trained research nurses. 14 Integrity of the data was maintained through ongoing curation and external data review by an independent chart abstractor.
Standard operating procedures were developed and implemented across all institutional centers to minimize variation in postinjury care, including early goal-directed resuscitation, strict glycemic control, venous thromboembolism prophylaxis, appropriate low tidal volume ventilation, ventilator-associated pneumonia management, and restrictive transfusion guidelines. [15] [16] [17] [18] While patients were admitted to the ICU, multiple-organ dysfunction scores for renal, hepatic, cardiovascular, metabolic, hematological, respiratory, and neurological systems were determined daily. [19] [20] [21] [22] Fifteen medications or medication classes were assessed for each patient and recorded as taken or not taken regularly before admission. These included NSAIDs, aspirin, other antiplatelet agents , β-blockers, antihypertensive medications, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, vasodilators, diuretics, calcium channel blockers, oral contraceptives, amphetamines, history of cocaine use, statins, and corticosteroids. The antihypertensive class is exclusive of aforementioned medications used as antihypertensives and included α 2 -agonists, direct renin inhibitors, aldosterone antagonists, and monoamine oxidase inhibitors. Amphetamines were prescribed for conditions such as attentiondeficit/hyperactivity disorder or narcolepsy. All medications were determined by reported history taken by the clinical coordinators during the enrollment and subsequent data entry as history became available. Subjects were interviewed regarding both prescription and over-the-counter use of these medications, where applicable.
Data collected from each subject included demographics, time from injury to admission, prehospital physiology and resuscitation, admission physiology and early resuscitation, admission laboratory results, markers of injury and shock severity, admission medications, comorbidities, and treating trauma center. Subjects were excluded if they had significant preexisting liver disease or were taking warfarin (Coumadin) before admission to exclude confounding variables of early coagulopathy.
The main outcome of interest was TIC, defined as an admission international normalized ratio (INR) of more than 1.5. The blood sample for INR was collected upon arrival to the study trauma center. The secondary outcome examined was clinically significant coagulopathy, defined as the need for transfusion of more than 2 units of fresh frozen plasma (FFP) or more than 1 pack of platelets in the first 6 hours after admission to the trauma center. This outcome was included to evaluate coagulopathy that required aggressive treatment early in the resuscitation phase, given the limitations of a single INR value, with some variability in determination from the time of injury and the lack of thromboelastography data that have been shown to be sensitive for traumatic coagulopathy but do not necessarily correlate with standard coagulation laboratory parameters. 23 The initial trauma resuscitation guidelines specified a hematocrit goal of 30% and central venous pressure of 15 mm Hg in accordance with practice at the initiation of the study; however, Kautza and colleagues 24 demonstrated an increasing use of plasma and platelets for trauma resuscitation in this data set in line with modern damage control and massive transfusion practices evolving during the study period. Forward stepwise logistic regression modeling was then used to examine the association of these outcomes with preadmission medications while controlling for confounders. Several clinical covariates were initially entered into the model to control for injury and resuscitation effects on coagulopathy. These included age, sex, time from injury to admission, lowest prehospital systolic blood pressure, highest prehospital heart rate, prehospital Glasgow Coma Scale Score, volume of prehospital packed red blood cell transfusion, volume of prehospital crystalloid infusion, volume of prehospital hypertonic saline infu-sion, admission alcohol level, initial base deficit, and injury severity score. To adjust for center-level effects, a 2-step cluster analysis was performed and incorporated into the logistic regression models. In addition to the aforementioned clinical covariates, all preadmission medications or medication classes were entered into the initial model and the overall number of medications taken. Finally, to control for potential interactions between medications and preadmission conditions, comorbidities were also entered into the outcome models. These broadly included cardiovascular, pulmonary, neurological, and renal diseases, immunodeficiencies, autoimmune and psychiatric disorders, history of past or current cancer, organ transplant, and several social conditions including alcohol, intravenous drug use, smoking, and homelessness. A P value of less than 0.2 for association of a covariate with the outcomes of interest was used for entry into the final model during the stepwise analysis. In addition to the aforementioned covariates and medications, the volume of packed red blood cell transfusion at 6 hours postadmission was included in the model assessing clinically significant coagulopathy. Model discrimination was assessed using the Omnibus test of model coefficients and Cstatistic, and goodness of fit was assessed using the Hosmer and Lemeshow test.
To further examine the effect of preadmission medications on the outcomes of interest independent of comorbid conditions, all medications found to be significantly associated with the primary or secondary outcomes were tested for association with individual comorbidities. The medication of interest was used as the outcome variable for a forward stepwise logistic regression model including all comorbidities present in the data set to identify any comorbidities that were significantly associated with the use of the preadmission medication in question. The stepwise logistic regression models for the primary and secondary outcomes were then repeated with the addition of interaction terms for each medication tested and any comorbidities that were significantly associated with its use in the aforementioned models.
Data analysis was conducted using SPSS, version 19 (IBM Corp., Armonk, NY). For univariate analyses, χ 2 tests were used to compare categorical variables, and Mann-Whitney tests were used to compare continuous variables. Continuous data are presented as median (interquartile range) or mean ± standard deviation, unless noted. A P value of 0.05 or less was considered significant. The institutional review board of each participating center approved the original prospective study.
RESULTS
Of the 2007 subjects in the prospective cohort study, 72 were excluded for preexisting liver disease and 38 were excluded for preadmission warfarin use, leaving 1897 subjects in the final analysis. The demographics and injury characteristics of this study population are shown in Table 1 . In these subjects, 22% presented with an INR of more than 1.5, 46% received more than 2 units of FFP or more than 1 pack of platelets within 6 hours of admission, and 15% met the definition of both TIC and clinically significant coagulopathy.
Three fourths of subjects did not take any of the 15 assessed preadmission medications. Subjects not taking any medication were younger, more severely injured, and had higher resuscitation requirements ( Table 2 ). Antihypertensive medications, followed by statins, were the most common preadmission medications in the cohort (Table 3) .
Stepwise logistic regression demonstrated that preadmission use of NSAIDs was independently associated with a 72% lower risk of TIC (Table 4 ). For the association of medications and TIC, no other medications retained a statistically significant association after 15 steps in the model. The Omnibus test of model coefficients was highly significant (P < 0.001), indicating that the covariates accounted for a significant amount of variation in the outcome of TIC. The Data presented as median (interquartile range) or mean ± SD. BD indicates base deficit; ISS, injury severity score; MOF, multiple-organ failure; PH, prehospital; PLT, platelets; PRBCs, packed red blood cells.
C-statistic was 0.81, indicating excellent discrimination of the model. The Hosmer-Lemeshow test was nonsignificant (P = 0.78), indicating that the model was well calibrated.
In analysis of clinically significant coagulopathy, stepwise logistic regression demonstrated that preadmission use of NSAIDs was independently associated with a 66% lower risk of clinically significant coagulopathy ( Table 5) . No other medications included in the model retained a statistically significant association with the need for more than 2 units of FFP or more than 1 pack of platelets in the first 6 hours after 14 steps in the model. The Omnibus test of model coefficients was again highly significant (P < 0.001), and the C-statistic was 0.90. The Hosmer-Lemeshow test was nonsignificant (P = 0.34). As NSAID use remained the only medication significantly associated with a reduction of both TIC and clinically significant coagulopathy, the association of NSAID use with comorbidities was further examined to attempt to exclude potential interactions between NSAID use and certain conditions as an explanation for these observations. Comorbidity predictors of NSAID use included prior myocardial infarction (P = 0.01), rheumatological disease (P < 0.01), and hyperlipidemia (P = 0.01). None of these comorbidities were associated with TIC, and both prior myocardial infarction and hyperlipidemia were associated with an increased risk for clinically significant coagulopathy (Table 4 ). For both the primary outcome of TIC and the secondary outcome of clinically significant coagulopathy, the interaction terms for NSAID use and prior myocardial infarction, NSAID use and rheumatological disease, and NSAID use and hyperlipidemia were not statistically significant (P > 0.05) and not retained in the final models. 
DISCUSSION
Despite an evolving understanding of the importance of TIC, insights into the pathophysiology or factors that predict the development of TIC are limited. In this study, we sought to identify whether prehospital use of NSAIDs was associated with a reduction in the incidence of TIC in a large cohort of severely injured patients. Upon analysis of presenting patient characteristics, multiple markers of increased injury severity, including elevated injury severity score, prehospital hypotension, and elevated base deficit, were associated with an increased odds ratio favoring the development of both TIC and clinically significant coagulopathy. Cardiac valvular disease was the only comorbidity strongly associated with both means of assessing coagulopathy; however, this did not appear to have an interaction with NSAID use. Moreover, 14 of 15 recorded prehospital medications failed to retain significance throughout the model. Strikingly, however, prehospital NSAID use was independently associated with a reduction in the incidence of TIC, both as measured by standard laboratory analysis at admission and in patients requiring FFP or platelet transfusion as a clinical measure of coagulopathy. We also analyzed the comorbidities with which NSAID use was associated with to understand whether the reduction in the incidence of TIC associated with NSAID use could be explained by another relationship. None of the interaction terms for NSAID use and associated comorbidities reached significance, and, in fact, 2 of these, myocardial infarction and hyperlipidemia, were actually associated with an increased risk of clinically significant coagulopathy. TIC has been shown by other authors to be associated with severe injury. 1, 2, 4, 25 In accordance with these observations, the current data suggest that common prehospital and admission predictors of elevated injury severity were also strongly associated with TIC and clinically significant coagulopathy, providing further evidence that the physiological chain of events associated with severe injury plays a strong role in coagulopathy. Time from injury was associated with a lower risk of TIC and clinically significant coagulopathy. The reason for this is not immediately clear, although it has been shown that TIC develops within minutes after injury. 26 This may represent a survival bias effect, with those surviving longer prehospital periods are less likely to have significant coagulopathy. Furthermore, patients transferred from other hospitals have a median time to admission of 3.7 hours compared with 1.0 hour for those brought directly to a study trauma center. Thus, those with longer preadmission periods may represent the majority of transfer subjects who received therapy at outside institutions not captured in the current database that altered the course of their coagulopathy, although transfer status itself was not associated with the current outcomes. Prehospital crystalloid was significantly associated with the development of TIC. Significant volumes of crystalloid could lead to a dilutional coagulopathy. 27, 28 This combination of time and dilution has been shown by other authors to be strongly linked with coagulopathy. 3, 29, 30 The fact that many of the injury severity predictors in the present study have previously been seen by other authors lends validity to the models.
We demonstrate here for the first time that prehospital NSAID use is associated with a significant reduction in the risk for TIC. As previously mentioned, this association was investigated by excluding a link between NSAID use and other comorbidities. Furthermore, NSAID use remained associated with a reduction in the incidence of TIC for both outcomes-the only medication to retain such significance. Retrospective analyses such as these limit the ability to assign causation; however, there is significant precedence in the literature to hypothesize potential explanations for the reduction in the incidence of TIC associated with NSAID use. NSAIDs are primarily used as anti-inflammatory agents and can have broad and nonspecific effects. A mechanistic link between inflammation and coagulopathy is well developed in the literature for multiple disease states. 9, [31] [32] [33] In fact, the powerful endogenous anticoagulant agents, antithrombin and activated protein C, also have anti-inflammatory properties. 34 Platelet activation is also significantly attenuated by NSAID use, and excessive platelet activation has been linked to the initiation of pathological coagulopathy. Other anti-inflammatory agents have been used in laboratory and clinical settings as specific therapies to reduce coagulopathy and subsequent morbidity, 35, 36 albeit with limited success. However, it is important to note that other anti-inflammatory agents tested in the model (aspirin, corticosteroids, antiplatelet agents) did not produce the same association with reduced incidence of TIC as NSAIDs. This could be explained by a potential off-target effect of NSAIDs or may be due to the complexity of the link between the inflammatory cascade and the induction of coagulopathy. Recent data from the Inflammation and the Host Response to Injury cohort, however, demonstrate that preadmission aspirin and antiplatelet use in patients receiving blood transfusion attenuates lung dysfunction and acute respiratory distress syndrome and showed a trend toward lower mortality. 11 This confirms, as seen in the current data, that preadmission anti-inflammatory medications have a role in altering the inflammatory cascade after severe trauma, with implications for outcomes and potential therapeutic strategies.
This analysis does have several potential limitations. This study is a secondary analysis of a prospective cohort study looking at the genomic and proteomic response after severe injury and hemorrhagic shock. As with any secondary analysis, data were not recorded to answer our specific hypothesis stated for this study. Important variables regarding specific medication use (as opposed to the general categories recorded), dose, and compliance were not recorded. Severity or specific characteristics of the listed comorbidities are not available for analysis. All patients in this cohort were severely injured by blunt mechanism and presented in hemorrhagic shock. This may limit the applicability of the results and conclusions to other cohorts. Potential unknown or unmeasured confounding variables may be responsible for the associations described and the conclusions formulated. Factor VIIa use was not originally a data point recorded for the overall cohort analysis, and although this would not affect the outcome of the elevated admission INR, factor VIIa use could confound the data related to the secondary outcome of clinically significant coagulopathy. Tranexamic acid was not included in the clinical protocols for the original prospective cohort study and no data were collected regarding its use, although it may have come into use over the study period at some centers. Finally, our secondary outcome was clinically significant coagulopathy, which we defined as the requirement for at least 2 units of FFP and/or platelet transfusion. This definition was chosen in an attempt to retrospectively analyze patients who may have had clinical evidence of impaired coagulation but would not have been identified by INR alone. Data regarding viscoelastic measurement of coagulation, such as thromboelastography, were not available for the cohort, and subsequent INR measurement after admission could be confounded by multiple factors. Thus, the triggers to initiate FFP or platelet transfusion were the best available characteristics to suggest the presence of coagulopathy. We recognize that some of these transfusion triggers may have been part of massive transfusion protocols and not directly in response to observed coagulopathy; however, the high incidence of TIC in patients requiring massive transfusion makes this a relevant population to include. Although no specific measurement of coagulopathy exists prove the presence of TIC, it is important to note that the secondary outcome identified similar predictors as compared with the primary outcome. This supports the choice of these transfusion thresholds as markers of clinically significant coagulopathy.
CONCLUSIONS
The present data suggest that prehospital use of NSAIDs was strongly associated with a reduced risk of presenting with an INR of more than 1.5 or the development of clinically significant coagulopathy as defined by a requirement for FFP and/or platelet transfusion. The novel potential link between NSAID use and the reduction in the incidence of TIC may be hypothesis generating as researchers investigate the pathophysiology of coagulopathy after sterile injury.
